All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead candidate, Darovasertib, shows promising efficacy in metastatic uveal melanoma, especially in combination with crizotinib, addressing a significant unmet medical need. IDE397, another key asset, demonstrated positive interim data in MTAP-deletion cancers, showing a 39% ORR and a strong safety profile.
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
The consensus price target hints at an 81.9% upside potential for IDEAYA Biosciences (IDYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline
IDEAYA Biosciences (IDYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
Ideaya Biosciences Inc. IDYA, a precision medicine oncology company, released interim Phase 2 clinical trial data.
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
IDEAYA Biosciences uses synthetic lethality to target genetic vulnerabilities in cancer cells, focusing on MTAP-deleted tumors. IDE397 demonstrated promising Phase 2 results with high response rates in MTAP-deleted solid tumors. Strategic partnerships with Pfizer, Amgen, Gilead, and GSK validate IDEAYA's technology and offer substantial potential milestone payments.
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
The mean of analysts' price targets for IDEAYA Biosciences (IDYA) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive News is Driving This Cancer Drug Maker's Stock Higher
Shares of IDEAYA Biosciences Inc. NASDAQ: IDYA are up more than 16% after announcing positive treatment data for its Phase 2 clinical trial. The company's pipeline candidate, IDE397, is an experimental drug designed to treat certain bladder and small-cell lung cancers.
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
IDEAYA Biosciences (IDYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IDEAYA Biosciences Soars on Cancer Drug Study Results
Shares of IDEAYA Biosciences (IDYA) took off in intraday trading Monday after the biotech announced positive results in a mid-stage study of its treatment for certain bladder and small-cell lung cancers.
